Top

Supportive Care in Cancer

Published in:

01-10-2018 | Original Article

Validation of the EPIPHANY index for predicting risk of serious complications in cancer patients with incidental pulmonary embolism

Authors: Shin Ahn, Tim Cooksley, Srinivas Banala, Luke Buffardi, Terry W. Rice

Published in: Supportive Care in Cancer | Issue 10/2018

Abstract

Purpose

The EPIPHANY index was developed to classify cancer associated pulmonary embolism (PE) into different risk categories using decision tree modeling. In this study, we tried to externally validate this index in a distinct group of patients solely composed of incidental PE (IPE).

Methods

A retrospective study of patients diagnosed with IPE in two Emergency Departments in the USA and South Korea from 2013 to 2014 was performed. The primary outcome was the occurrence of a serious medical complication within 15 days of presentation to ED. Thirty-day complication was the secondary outcome. Cumulative hazard curves for each prognostic category were drawn to show the change in hazards over time.

Results

A total of 258 patients with IPE were included (193 from MD Anderson Cancer Center and 65 from Asan Medical Center). Serious complication within 15 days occurred in 23 (8.9%) patients. The risk of overall 15-day and 30-day serious complications increased with each category (low, intermediate, and high risk: 3.4, 8.9, and 23.8%, P = 0.033; 6.9, 9.5, and 33.3%, P = 0.011). Cumulative hazard curves for each prognostic category were drawn and the survival functions factored by prognostic categories were significantly different over 15 days (P = 0.015) and 30 days (P = 0.001).

Conclusions

Our study suggests the EPIPHANY index could be a useful adjunct tool in risk stratification of cancer patients with IPE.

Available only for authorised users

Khorana AA, Francis CW, Culakova E, Kuderer NM, Lyman GH (2007) Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy. J Thromb Haemost 5(3):632–634. https://doi.org/10.1111/j.1538-7836.2007.02374.x CrossRefPubMed

Khorana AA, O'Connell C, Agnelli G, Liebman HA, Lee AY, Subcommittee on H, Malignancy of the SSCotI (2012) Incidental venous thromboembolism in oncology patients. J Thromb Haemost 10(12):2602–2604CrossRefPubMedPubMedCentral

Kearon C, Akl EA, Comerota AJ, Prandoni P, Bounameaux H, Goldhaber SZ, Nelson ME, Wells PS, Gould MK, Dentali F, Crowther M, Kahn SR (2012) Antithrombotic therapy for VTE disease: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 141(2 Suppl):e419S–e496S. https://doi.org/10.1378/chest.11-2301 CrossRefPubMedPubMedCentral

den Exter PL, Hooijer J, Dekkers OM, Huisman MV (2011) Risk of recurrent venous thromboembolism and mortality in patients with cancer incidentally diagnosed with pulmonary embolism: a comparison with symptomatic patients. J Clin Oncol 29(17):2405–2409. https://doi.org/10.1200/JCO.2010.34.0984 CrossRef

Barritt DW, Jordan SC (1960) Anticoagulant drugs in the treatment of pulmonary embolism. A controlled trial. Lancet 1(7138):1309–1312CrossRefPubMed

Carson JL, Kelley MA, Duff A, Weg JG, Fulkerson WJ, Palevsky HI, Schwartz JS, Thompson BT, Popovich J Jr, Hobbins TE, Spera MA, Alavi A, Terrin ML (1992) The clinical course of pulmonary embolism. N Engl J Med 326(19):1240–1245. https://doi.org/10.1056/NEJM199205073261902 CrossRefPubMed

den Exter PL, Gomez V, Jimenez D, Trujillo-Santos J, Muriel A, Huisman MV, Monreal M, Registro Informatizado de la Enfermedad TromboEmbolica I (2013) A clinical prognostic model for the identification of low-risk patients with acute symptomatic pulmonary embolism and active cancer Chest 143 (1):138–145. doi:https://doi.org/10.1378/chest.12-0964

Kline JA, Roy PM, Than MP, Hernandez J, Courtney DM, Jones AE, Penaloza A, Pollack CV, Jr. (2012) Derivation and validation of a multivariate model to predict mortality from pulmonary embolism with cancer: the POMPE-C tool. Thromb Res 129 (5):e194–e199. doi:https://doi.org/10.1016/j.thromres.2012.03.015

Font C, Carmona-Bayonas A, Beato C, Reig O, Saez A, Jimenez-Fonseca P, Plasencia JM, Calvo-Temprano D, Sanchez M, Benegas M, Biosca M, Varona D, Vicente MA, Faez L, Solis MD, de la Haba I, Antonio M, Madridano O, Castanon E, Martinez MJ, Marchena P, Ramchandani A, Dominguez A, Puerta A, Martinez de la Haza D, Pueyo J, Hernandez S, Fernandez-Plaza A, Martinez-Encarnacion L, Martin M, Marin G, Ayala F, Vicente V, Otero R, Asociacion para la Investigacion de la Enfermedad Tromboembolica de la region de M (2017) Clinical features and short-term outcomes of cancer patients with suspected and unsuspected pulmonary embolism: the EPIPHANY study. Eur Respir J 49(1):1600282. https://doi.org/10.1183/13993003.00282-2016 CrossRefPubMed

10.

Ahn S, Lee YS, Kim WY, Lim KS, Lee JL (2016) Prognostic value of treatment setting in patients with cancer having pulmonary embolism. Clin Appl Thromb Hemost. https://doi.org/10.1177/1076029615625826

11.

Carmona-Bayonas A, Jimenez-Fonseca P, Font C, Fenoy F, Otero R, Beato C, Plasencia JM, Biosca M, Sanchez M, Benegas M, Calvo-Temprano D, Varona D, Faez L, de la Haba I, Antonio M, Madridano O, Solis MP, Ramchandani A, Castanon E, Marchena PJ, Martin M, Ayala de la Pena F, Vicente V (2017) Predicting serious complications in patients with cancer and pulmonary embolism using decision tree modelling: the EPIPHANY index. Br J Cancer 116(8):994–1001. https://doi.org/10.1038/bjc.2017.48 CrossRefPubMedPubMedCentral

12.

Carmona-Bayonas A, Font C, Jimenez-Fonseca P, Fenoy F, Otero R, Beato C, Plasencia J, Biosca M, Sanchez M, Benegas M, Calvo-Temprano D, Varona D, Faez L, Vicente MA, de la Haba I, Antonio M, Madridano O, Ramchandani A, Castanon E, Marchena PJ, Martinez MJ, Martin M, Marin G, Ayala de la Pena F, Vicente V, Asociacion de Investigacion de la Enfermedad Tromboembolica de la Region de M (2016) On the necessity of new decision-making methods for cancer-associated, symptomatic, pulmonary embolism Thromb Res 143:76–85. doi:https://doi.org/10.1016/j.thromres.2016.05.010

13.

Konstantinides SV, Torbicki A, Agnelli G, Danchin N, Fitzmaurice D, Galie N, Gibbs JS, Huisman MV, Humbert M, Kucher N, Lang I, Lankeit M, Lekakis J, Maack C, Mayer E, Meneveau N, Perrier A, Pruszczyk P, Rasmussen LH, Schindler TH, Svitil P, Vonk Noordegraaf A, Zamorano JL, Zompatori M, Task Force for the D, Management of Acute Pulmonary Embolism of the European Society of C (2014) 2014 ESC guidelines on the diagnosis and management of acute pulmonary embolism. Eur Heart J 35 (43):3033-3069, 3069a-3069k. doi:https://doi.org/10.1093/eurheartj/ehu283

14.

Condliffe R, Elliot CA, Hughes RJ, Hurdman J, Maclean RM, Sabroe I, van Veen JJ, Kiely DG (2014) Management dilemmas in acute pulmonary embolism. Thorax 69(2):174–180. https://doi.org/10.1136/thoraxjnl-2013-204667 CrossRefPubMed

15.

Aujesky D, Perrier A, Roy PM, Stone RA, Cornuz J, Meyer G, Obrosky DS, Fine MJ (2007) Validation of a clinical prognostic model to identify low-risk patients with pulmonary embolism. J Intern Med 261(6):597–604. https://doi.org/10.1111/j.1365-2796.2007.01785.x CrossRefPubMed

16.

Jimenez D, Aujesky D, Moores L, Gomez V, Lobo JL, Uresandi F, Otero R, Monreal M, Muriel A, Yusen RD, Investigators R (2010) Simplification of the pulmonary embolism severity index for prognostication in patients with acute symptomatic pulmonary embolism. Arch Intern Med 170(15):1383–1389. https://doi.org/10.1001/archinternmed.2010.199 CrossRefPubMed

17.

Cooksley T, Rice T (2017) Emergency oncology: development, current position and future direction in the USA and UK. Support Care Cancer 25(1):3–7. https://doi.org/10.1007/s00520-016-3470-1 CrossRefPubMed

18.

Banala SR, Yeung SJ, Rice TW, Reyes-Gibby CC, Wu CC, Todd KH, Peacock WF, Alagappan K (2017) Discharge or admit? Emergency department management of incidental pulmonary embolism in patients with cancer: a retrospective study. Int J Emerg Med 10(1):19. https://doi.org/10.1186/s12245-017-0144-9 CrossRefPubMedPubMedCentral

19.

Buswell LA, Ponte PR, Shulman LN (2009) Provider practice models in ambulatory oncology practice: analysis of productivity, revenue, and provider and patient satisfaction. J Oncol Pract 5(4):188–192. https://doi.org/10.1200/JOP.0942006 CrossRefPubMedPubMedCentral

20.

Cooksley T, Holland M, Klastersky J (2015) Ambulatory outpatient management of patients with low risk febrile neutropaenia. Acute Med 14(4):178–181PubMed

Title: Validation of the EPIPHANY index for predicting risk of serious complications in cancer patients with incidental pulmonary embolism
Authors: Shin Ahn
Tim Cooksley
Srinivas Banala
Luke Buffardi
Terry W. Rice
Publication date: 01-10-2018
Publisher: Springer Berlin Heidelberg
Published in: Supportive Care in Cancer / Issue 10/2018
Print ISSN: 0941-4355
Electronic ISSN: 1433-7339
DOI: https://doi.org/10.1007/s00520-018-4235-9

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 10/2018

Cancer cost communication: experiences and preferences of patients, caregivers, and oncologists—a nationwide triad study

The perceptions and experiences of osteopathic treatment among cancer patients in palliative care: a qualitative study

Online information and support needs of women with advanced breast cancer: a qualitative analysis

Predicting symptoms of anxiety and depression in patients living with advanced cancer: the differential roles of hope and optimism

The effects of an educational program for non-physician health care providers regarding fertility preservation

Patterns of interactions among patients with advanced pancreatic cancer, their caregivers, and healthcare providers during symptom discussions

Keynote webinar | Spotlight on antibody–drug conjugates in cancer